Avalo Therapeutics, Inc. (AVTX) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Avalo Therapeutics, Inc. (AVTX) closed at USD 12.01 on 2026-10-15, a change of -33.4 % over the past year, with a market capitalization of USD 604.41M.

Avalo Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Avalo Therapeutics, Inc. key figures

Previous close

USD 12.01 (2026-10-15)

1-year change

-33.4 %

Market cap

USD 604.41M

Enterprise value

USD 204.38M

P/E ratio (trailing)

-2.62

P/E ratio (forward)

-4.16

EPS (trailing)

-4.31

EPS (forward)

-2.71

PEG ratio

n/a

Price to book

1.33

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

9.77

Employees

33

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Avalo Therapeutics, Inc. and compare it with other stocks.